ITC Nexus, engaged in hemostasis management and Point-of-Care (POC) testing, has acquired Accumetrics, a medical device company engaged in the development and marketing of comprehensive suite of assays for the assessment of platelet function, for an undisclosed amount.
The combined company will be named Accriva Diagnostics, and its corporate headquarters will be established in San Diego, US. The terms of the transaction were, however, not disclosed.
Accriva Diagnostics will combine ITC’s Hemochron and Accumetrics’ VerifyNow product lines to create a hospital-based POC cardiovascular diagnostics business.
Accumetrics CEO Timothy I Still said, "I am confident that combining Accumetrics with ITC provides the best opportunity to accelerate the global adoption of the VerifyNow system."
ITC CEO John Sperzel noted the company has a history of innovation and leadership in Point-of-Care coagulation testing and Accumetrics is a pioneer and leader in Point-of-Care platelet function testing.
According to the company, the integration of ITC and Accumetrics businesses will commence immediately.
While Sperzel will serve as CEO of the combined company, Greg Tibbitts, CFO of Accumetrics, will serve as CFO of the combined company.
ITC develops, manufactures, and markets the Hemochron product line, a POC system used to measure clotting activity for patients undergoing anticoagulation therapy.
Accumetrics develops, manufactures, and markets the VerifyNow product line, a POC system used to measure platelet reactivity following antiplatelet therapies, including ADP receptor antagonists and aspirin.